In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities Association (OFA), which called the FDA’s decision to remove tirzepatide from the shortage list a “reckless and arbitrary decision—lacking any semblance of lawful process.”
HealthDay on MSN1d
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for NowOn October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of ...
Health on MSN1d
What the End of a Tirzepatide Shortage Would Mean for Access to Compounded Weight Loss DrugsIn response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...
Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...
The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...
But when the FDA announced on Oct. 2 that the shortage of tirzepatide had ended, that meant compounding pharmacies had to stop making it. For now though, according to the recent court filing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback